ClinicalTrials.gg
RecruitingNCT07220525DISCRETE AFUpdated Oct 2, 2026

Disrupted Sleep and Concurrent Ectopy or Atrial Fibrillation

An interventional study of HGNS Use Randomized Instructions in Obstructive Sleep Apnea, Premature Ventricular Contraction (PVC) and Atrial Fibrillation (AF), sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

Whereas the available evidence mostly supports chronic sleep disruption as a risk factor for incident AF, less is known about the near-term risk of a discrete atrial fibrillation (AF) episode following a night of disrupted or poor-quality sleep. This prospective, randomized, case-crossover study aims to examine the acute effects of sleep disruption on clinically relevant cardiac ectopy pertinent to AF.

Read the detailed description

One hundred patients aged 21 years or older who have a hypoglossal nerve stimulation (HGNS) device implanted for obstructive sleep apnea, without a history of permanent AF, not on Class 1 or 3 antiarrhythmic medications and willing to participate in the study, will be randomized to "off-on" versus "on-off" periods (where "off" is turning off the HGNS device for one night and "on" is turning on the HGNS device), assuring no more than two consecutive days of either device use or not, over the ensuing 14 days. Participants will be fitted with an automatically recording electrocardiographic monitor. The primary endpoint will be the daily number of cardiac ectopic beats, and secondary endpoints: daily number of PACs, daily number of PVCs, and daily presence versus absence of AF episodes ≥ 30 seconds. Primary analyses will employ intention-to-treat principles, examining randomization assignment as the primary predictor.

02

Conditions studied

  • Obstructive Sleep Apnea
  • Premature Ventricular Contraction (PVC)
  • Atrial Fibrillation (AF)
  • Premature Atrial Contraction

Keywords

  • Sleep Apnea
  • Hypoglossal Nerve Stimulation Device
  • Atrial Fibrillation
  • Upper Airway Stimulation
  • Premature Atrial Contraction
  • Premature Ventricular Contraction
03

In context

Sleep Apnea, Obstructive

2,240 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.

This study's planned enrollment of 100 is above the median of 52 across 1,472 interventional studies indexed under Sleep Apnea, Obstructive.

Browse Sleep Apnea, Obstructive studies →

Lead sponsor

University of California, San Francisco is the lead sponsor of 2,169 studies on the registry; 372 are open to participants now.

Of its 267 completed or terminated interventional studies of FDA-regulated products, 202 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are age 21 years or older
  • Have a HGNS device implanted for obstructive sleep apnea and followed up at UCSF Health
  • Are willing to abstain from using the upper airway stimulation device for no more than two consecutive days as instructed over the 14-day trial period
  • Able and willing to provide written

Exclusion criteria

Exclusion Criteria:

  • Currently pregnant or trying to get pregnant
  • Are currently taking class 1 or 3 anti-arrhythmic medications
  • Have a history of permanent AF or expected to have continuous AF throughout the study period
  • Have congenital heart disease
  • Ventricular pacing >40%
  • Are unable to read or sign to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    HGNS 'Off' Case-Crossover Arm

    On a given day of the 14-day study period, participants may be randomly assigned to turn off/not use their HGNS device during that night of sleep. Participants will not receive the same randomization assignment more than two consecutive days in a row.

    Device: HGNS Use Randomized Instructions

  • Experimental
    HGNS 'On' Case-Crossover Arm

    On a given day of the 14-day study period, participants may be randomly assigned to turn on/use their HGNS device during that night of sleep. Participants will not receive the same randomization assignment more than two consecutive days in a row.

    Device: HGNS Use Randomized Instructions

Interventions

  • DeviceHGNS Use Randomized Instructions

    In this intervention assignment, participants will be instructed to turn off/not use their HGNS device during that night of sleep. HGNS 'on': In this intervention assignment, participants will be instructed to turn on/use their HGNS device during that night of sleep.

06

What researchers measure

Primary outcomes

  1. Ectopic beats

    Daily number of ectopic beats as recorded with the adhesive heart monitor

    Time frame: 24-hour time period

Secondary outcomes

  1. Premature Atrial Contractions (PACs)

    Daily number of PACs as recorded with the adhesive heart monitor

    Time frame: 24-hour time period

  2. Premature Ventricular Contractions (PVCs)

    Daily number of PVCs as recorded with the adhesive heart monitor

    Time frame: 24-hour time period

  3. Atrial Fibrillation (AF)

    Daily presence of AF ≥30 seconds as recorded with the adhesive heart monitor

    Time frame: 24-hour time period

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Updates

1 registry update since Sep 25, 2026
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07220525
Responsible party
Sponsor
First posted
Oct 24, 2025
Start date
Dec 15, 2025
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Hannah Oo, BS
Contact
hannah.oo@ucsf.edu
415-476-4999
Bella Peña, BA
Contact
bella.pena@ucsf.edu
415-502-3053
Gregory Marcus, MD, MAS
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion